Syngen Biotech Co.,Ltd. (TPEX:8279)

Syngen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	316.91	341.93	366.89	246.05	314.8	423.42
Cash & Short-Term Investments	316.91	341.93	366.89	246.05	314.8	423.42
Cash Growth	-14.41%	-6.80%	49.11%	-21.84%	-25.65%	-18.48%
Accounts Receivable	430.27	422.56	387.8	472.06	388.16	298.71
Other Receivables	0	0	0	0	0	-
Receivables	430.27	422.56	387.8	472.06	388.16	298.71
Inventory	350.73	345.62	348.99	369.35	291.96	259.78
Prepaid Expenses	38.87	44.93	28.77	25.42	23.17	34.92
Total Current Assets	1,137	1,155	1,132	1,113	1,018	1,017
Property, Plant & Equipment	1,511	1,518	1,526	1,543	1,035	1,035
Long-Term Investments	326.21	324.34	331.74	313.75	293.55	2.7
Other Intangible Assets	27.9	27.57	24.13	22.96	23.42	27.32
Long-Term Deferred Tax Assets	17.34	18.86	17.44	16.21	12.32	10.39
Other Long-Term Assets	46.39	38.4	73.21	58.7	28.23	28.94
Total Assets	3,068	3,085	3,106	3,071	2,416	2,127
Accounts Payable	243.53	255.87	226.47	248.45	236.86	140.59
Accrued Expenses	-	78.84	72.8	79.89	64.72	3.94
Short-Term Debt	60	-	80	230	-	50
Current Portion of Long-Term Debt	-	59.03	59.03	-	-	-
Current Portion of Leases	14.7	14.71	13.38	14.85	13.7	14.11
Current Income Taxes Payable	49.46	35.18	62.06	76.99	58.39	28.12
Current Unearned Revenue	34.06	24.83	20.04	6.73	6.55	1.97
Other Current Liabilities	295.14	51.7	50.81	62.56	38.4	73.27
Total Current Liabilities	696.89	520.16	584.58	719.47	418.61	312
Long-Term Debt	49.19	163.95	222.97	182	50	-
Long-Term Leases	156.69	160.25	163.1	173.93	172.39	186.17
Long-Term Deferred Tax Liabilities	3.22	4.17	3.98	3.93	3.16	2.58
Total Liabilities	905.99	848.52	974.63	1,079	644.16	500.74
Common Stock	271.01	271.01	271.01	271.01	271.01	271.01
Additional Paid-In Capital	618.24	618.24	618.2	618.06	612.83	610.54
Retained Earnings	1,270	1,344	1,243	1,103	887.88	744.67
Comprehensive Income & Other	2.99	2.73	-0.26	-0.07	-0.36	-0.12
Shareholders' Equity	2,162	2,236	2,132	1,992	1,771	1,626
Total Liabilities & Equity	3,068	3,085	3,106	3,071	2,416	2,127
Total Debt	280.58	397.93	538.49	600.78	236.08	250.28
Net Cash (Debt)	36.33	-56	-171.6	-354.73	78.72	173.14
Net Cash Growth	-	-	-	-	-54.53%	-52.69%
Net Cash Per Share	1.34	-2.06	-6.33	-13.07	2.90	6.38
Filing Date Shares Outstanding	27.05	27.1	27.1	27.1	27.1	27.1
Total Common Shares Outstanding	27.05	27.1	27.1	27.1	27.1	27.1
Working Capital	439.89	634.89	547.87	393.41	599.48	704.84
Book Value Per Share	79.91	82.51	78.66	73.49	65.36	60.00
Tangible Book Value	2,134	2,209	2,107	1,969	1,748	1,599
Tangible Book Value Per Share	78.88	81.49	77.76	72.64	64.50	58.99
Land	-	251	251	251	-	-
Buildings	-	729.7	717.09	702.28	532.98	529.5
Machinery	-	1,022	871.44	841.51	693.37	656.19
Construction In Progress	-	74.67	146.33	114.01	111.97	79.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.